Bristol-Myers Squibb (BMY) Tops Q4 EPS by 1c

Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.83, $0.01 better than the analyst estimate of $1.82. Revenue for the quarter came in at $12 billion versus the consensus estimate of $12.12 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2022 EPS of $7.65-$7.95.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Is the global equity rally broadening? UBS weighs in
• Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance